For superficial STAT3-dependent cancers such as HNSCC, intratumoral injection is expected to enhance the efficacy of PROTACs, as well as overcome the potential risk to normal tissues or organs. This evidence concerns the gene STAT3 and head and neck squamous cell carcinoma.